Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$47.55 +7.3%	$40.14	$26.20 ▼ $63.50	$2.04B	1.47	563,959 shs	507,962 shs
CGON CG Oncology	$26.90 +0.8%	$25.88	$14.80 ▼ $40.47	$2.03B	0.86	846,613 shs	349,450 shs
IDYA IDEAYA Biosciences	$22.09 +0.8%	$20.28	$13.45 ▼ $44.42	$1.92B	0.03	1.03 million shs	522,894 shs
ZVRA Zevra Therapeutics	$9.79 +4.0%	$8.57	$4.20 ▼ $10.03	$514.53M	1.97	685,187 shs	1.18 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	+7.29%	+8.54%	+28.24%	+47.12%	+26.80%
CGON CG Oncology	+0.81%	+3.16%	+0.39%	+56.37%	-12.76%
IDYA IDEAYA Biosciences	+0.78%	-0.90%	+2.08%	+50.17%	-33.64%
ZVRA Zevra Therapeutics	+3.99%	+5.44%	+10.32%	+38.99%	+127.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	2.8941 of 5 stars	3.5	2.0	0.0	2.3	4.2	0.0
CGON CG Oncology	2.4153 of 5 stars	4.5	3.0	0.0	0.0	0.8	0.0
IDYA IDEAYA Biosciences	3.5468 of 5 stars	3.5	1.0	4.4	1.3	1.7	0.0
ZVRA Zevra Therapeutics	2.6045 of 5 stars	3.6	3.0	0.0	3.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$95.80	101.47% Upside
CGON CG Oncology	3.00	Buy	$58.67	118.13% Upside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$53.42	141.81% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.14	136.51% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, APGE, CGON, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	APGE Apogee Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/29/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
CGON CG Oncology	$1.14M	1,798.19	N/A	N/A	$9.63 per share	2.79
IDYA IDEAYA Biosciences	$7M	276.38	N/A	N/A	$12.25 per share	1.80
ZVRA Zevra Therapeutics	$23.61M	22.66	N/A	N/A	$0.74 per share	13.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$3.60	N/A	N/A	N/A	N/A	-28.35%	-26.98%	8/11/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-29.28%	-27.68%	8/5/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	48.93	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest ZVRA, APGE, CGON, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	15.82	15.82
CGON CG Oncology	N/A	30.97	30.97
IDYA IDEAYA Biosciences	N/A	13.92	13.92
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CGON CG Oncology	26.56%
IDYA IDEAYA Biosciences	98.29%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
CGON CG Oncology	7.40%
IDYA IDEAYA Biosciences	2.50%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.05 million	26.35 million	Optionable
CGON CG Oncology	61	76.22 million	70.58 million	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	85.39 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

ZVRA, APGE, CGON, and IDYA Headlines

Recent News About These Companies

What is HC Wainwright's Forecast for ZVRA Q2 Earnings?

2 hours ago | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Hits New 12-Month High - Still a Buy?

3 hours ago | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 5.9% - Still a Buy?

July 3 at 12:48 PM | marketbeat.com

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?

July 3 at 9:21 AM | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at HC Wainwright

July 2 at 8:44 AM | marketbeat.com

Carret Asset Management LLC Buys Shares of 36,140 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 21, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts

June 20, 2025 | marketbeat.com

Cantor Fitzgerald Predicts ZVRA FY2026 Earnings

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 9, 2025 | marketbeat.com

Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 5, 2025 | marketbeat.com

Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 31, 2025 | finanznachrichten.de

Zevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth Strategy

May 31, 2025 | nasdaq.com

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025 | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27, 2025 | insidermonkey.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 13, 2025 | taiwannews.com.twT

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, APGE, CGON, and IDYA Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$47.55 +3.23 (+7.29%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$47.38 -0.17 (-0.37%)

As of 07/3/2025 04:20 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

CG Oncology NASDAQ:CGON

$26.90 +0.22 (+0.81%)

Closing price 07/3/2025 01:04 PM Eastern

Extended Trading

$26.90 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

IDEAYA Biosciences NASDAQ:IDYA

$22.09 +0.17 (+0.78%)

As of 07/3/2025 01:04 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Zevra Therapeutics NASDAQ:ZVRA

$9.78 +0.38 (+3.99%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$9.54 -0.24 (-2.45%)

As of 07/3/2025 04:48 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time